Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
This study is ongoing, but not recruiting participants.
Study NCT00303290 Information provided by M.D. Anderson Cancer Center
First Received: March 15, 2006 Last Updated: September 9, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Myeloid Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Ara-C (cytosine arabinoside)
Additional drug interventions recognized in this trial
Cytarabine
Interferon Alfa-2a
Interferon Alfa-2b
Interferon Type I, Recombinant
Interferon-alpha
Interferons
Peginterferon alfa-2b
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Schering-Plough
Back to top of Main Content
